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National Healthcare Safety Network (NHSN)
The NHSN is a secure, internet-based surveillance system that integrates former CDC surveillance
systems, including the National Nosocomial Infections Surveillance System (NNIS), National Surveillance
System for Healthcare Workers (NaSH), and the Dialysis Surveillance Network (DSN).
NHSN enables healthcare facilities to collect and use data about healthcare-associated infections,
adherence to clinical practices known to prevent healthcare-associated infections, the incidence or
prevalence of multidrug-resistant organisms within their organizations, trends and coverage of healthcare
personnel safety and vaccination, and adverse events related to the transfusion of blood and blood
products. Some U.S. states utilize NHSN as a means for healthcare facilities to submit data on
healthcare-associated infections (HAIs) mandated through their specific state legislation.
The NHSN includes four components, each concerned with various aspects of control and prevention of
HAIs. Those four components are Patient Safety, Healthcare Personnel Safety, Biovigilance, and
Research and Development as illustrated below in Figure 1. NHSN users do not use the Research and
Development Component of the system. NHSN users do however, access and participate in the Patient
Safety, Healthcare Personnel Safety, and Biovigilance Components of NHSN.
A facility (acute care hospital, ambulatory surgery center, outpatient dialysis center) may use one, two, or
all three NHSN components concurrently. Even if a facility is using more than one NHSN component,
there must be only one designated NHSN Facility Administrator that is responsible for activating and
deactivating components for that facility. If your facility is already using NHSN for another purpose, you
will not need to complete the entire enrollment process to use the Biovigilance Component. Instead, the
NHSN Facility Administrator will activate the Biovigilance Component, designate a BV Component
Primary Contact, and add at least one NHSN User with rights to the BV Component. Please contact your
Infection Prevention team to determine if your facility is already enrolled in NHSN. Contact nhsn@cdc.gov
if you have questions about the enrollment or component activation process.
Figure 1. NHSN Components.
NHSN
Components
Patient Safety Healthcare
Personnel Safety
Biovigilance Research and
Development
Research and Development
Research and Development is concerned with enabling infection control software systems, private or
public, to communicate with the NHSN thereby reducing manual data entry. This component involves
internal activities at CDC in partnership with software and data messaging specialists.
Patient Safety
Within the Patient Safety Component, like-types of surveillance are grouped into modules, each
concerned with healthcare procedures, devices, or medications associated with HAIs. Specific types of
surveillance within the Patient Safety Component are outlined below:
• Device-associated Module:
o CLABSI - Central line-associated bloodstream infection
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o CLIP - Central line insertion practices adherence
o VAP - Ventilator-associated pneumonia
o CAUTI - Catheter-associated urinary tract infection
o DE - Dialysis Event
• Procedure-associated Module:
o SSI - Surgical site infection
o PPP - Post-procedure pneumonia
• Medication-associated Module:
o AUR - Antimicrobial use and resistance options
• Multidrug-Resistant Organisms/Clostridium difficile-associated Disease (MDRO/CDAD) Module
• Vaccination Module
Instructions and standardized surveillance methods and definitions for each module of the Patient Safety
Component are provided in individual protocols available on the NHSN website. Modules may be used
singly or simultaneously and each module has its own minimum time-period for required participation (see
individual modules). Regardless of the combination of modules a facility chooses to participate in, a total
of 6 months of data must be reported annually to NHSN for continued participation.
Healthcare Personnel Safety
There are two modules within the Healthcare Personnel Safety (HPS) Component of NHSN: the
Blood/Body Fluid Exposure Module and the Influenza Vaccination Module. The Blood/Body Fluids
Exposure and the Influenza Vaccination Modules may be used separately or simultaneously. Instructions
and standardized surveillance methods and definitions for each module are provided in the NHSN Manual
found on the NHSN website.
Biovigilance
The Biovigilance Component of NHSN was developed in collaboration with the transfusion and transplant
communities. Biovigilance includes the collection of adverse event data to improve outcomes in the use of
blood products, organs, tissues, and cellular therapies. The Hemovigilance Module is the first module of
the Biovigilance Component to be developed in NHSN. This module is designed for staff in healthcare
facility transfusion services to track adverse events, including recipient adverse reactions and quality
control incidents, related to blood transfusion.
Biovigilance Component
Patient safety related to medical intervention has become an increasing public health concern in recent
years. The Patient Safety and Quality Improvement Act of 2005 (Public Law 109-41) intends to improve
patient safety by encouraging voluntary and confidential reporting of events that adversely affect patients.
In 2006, the Department of Health and Human Services’ (HHS) Advisory Committee on Blood Safety and
Availability (ACBSA) convened to make recommendations to improve patient safety related to transfusion
and transplantation. ACBSA membership includes liaisons from federal public health agencies as well as
representatives from industry, patient advocates, and the blood collection and transfusion communities.
A recommendation was given to the Secretary of HHS by ACSBA that a national system was needed for
surveillance of recipient outcomes of blood and blood products. Such surveillance, often referred to as
hemovigilance, exists in most other developed countries, but not in the United States. Subsequently, the
American Association of Blood Banks (AABB) formed an Inter-organizational Task Force on Biovigilance,
with representation from both governmental and non-governmental organizations in the United States.
The committee defined as their main task to develop “a comprehensive and integrated national patient
safety program to collect, analyze, and report on the outcomes of collection and transfusion and/or
transplantation of blood components and derivatives, cells, tissues, and organs. The program should be
outcome driven with the objectives of providing early warning systems of safety issues, exchanging of
Page 4 of 30
 
July 2010
 
   
 
    
  
             
              
             
 
                  
             
               
             
               
   
 
  
              
                  
                 
   
 
                   
               
              
              
               
          
                
             
               
            
         
 
               
              
               
              
             
              
             
              
     
 
               
              
                  
                
                   
             
 
  
              
               
               
            
        
 
     
                 
NHSN Biovigilance Component
Protocol
safety information, and promoting education and the application of evidence for practice improvement.”
While biovigilance also includes organ and tissue transplant safety, blood safety, or hemovigilance, was
the first topic of focus in the development of a national surveillance system.
After a review of the different systems that could be used to collect transfusion safety data, the AABB
Biovigilance Task Force identified CDC’s National Healthcare Safety Network (NHSN) as the surveillance
system that most closely met the data requirements for a national surveillance system for blood
transfusion adverse event data collection. The Hemovigilance Module of the Biovigilance Component is
intended to capture both adverse transfusion reactions and errors and accidents for the purpose of
evaluating patient safety.
Hemovigilance Module
Based on the last published Nationwide Blood Collection and Utilization Survey Report (NBCUS)1, the
total supply of whole blood and red blood cells collected in the United States in 2004 was approximately
15 million units. Recipients received, on average, 2.7 units each resulting in a national estimate of 5.3
million patients transfused.
While the risk of infectious disease as a result of transfusion has been estimated (for example, the risk of
HIV is approximately 1 in 2 million), data on transfusion related, non-infectious adverse reactions and
incidents associated with transfusion are not collected in the United States using a comprehensive
reporting system with standard definitions. Therefore, estimates of the burden of adverse events related
to transfusion are not possible. The 2004 NBCUS found that 1,322 medical facilities reported 32,128
transfusion-related reactions that required diagnostic or therapeutic intervention1. While any transfusion-
associated adverse reaction is considered rare, the general consensus in the United States is that there
could be considerable underreporting based on surveillance reports of similar events from national
surveillance programs in the United Kingdom and Canada. Collection of data on all adverse events,
including reactions, incidents, and near-misses, would provide the basis for interventions and
implementation of best practices designed to improve transfusion safety.
Five layers of safeguards established by the Food and Drug Administration (FDA) have become standard
operating procedure for blood establishments and others involved in the collection and distribution of
blood and blood products. These safeguards include screening of blood donors, testing of blood for
bloodborne pathogens (including HIV, Hepatitis B & C viruses, Treponema pallidum (syphilis), West Nile
virus and others), maintaining lists of deferred donors (persons either temporarily or permanently
excluded from blood donation), routine quarantine of all blood products until infectious disease testing
and final donor eligibility determination has been completed, and investigation of any problems
associated with blood products including safeguard failures, errors, accidents, or any other event that
could jeopardize blood product safety.
Despite the rigorous safeguards in place, non-infectious complications of transfusion can still occur due to
the complex physiological mechanisms involved in transfusions. In addition, the risk of error associated
with administration of a particular blood product to a particular patient is a persistent concern. In 1999, the
Institute of Medicine report, To Err is Human, estimated that between 44,000 and 98,000 Americans die
each year as a result of medical errors. In terms of blood safety, mistransfusion of blood (failure to give
the right product to the right patient) is the error of greatest concern.
Adverse Reactions
Over the past three decades, emphasis on the detection and prevention of infectious disease
transmission through transfused blood and blood products led to FDA requirements for routine testing of
donated blood for a variety of bloodborne pathogens. With enactment of these testing requirements and
the subsequent decrease in the incidence of transfusion transmitted infections, reactions with non­
infectious causes became more apparent. A recent review article2 classified these reactions as early
(onset during or within hours of the transfusion) or late (onset days to months following transfusion) and
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provided estimates of reaction occurrence. Although the estimates varied considerably depending on the
study, severe reactions have fatal event rates of 1 per million to 1 per 8 million transfused components.
Severe early reactions such as Transfusion Related Acute Lung Injury (TRALI) showed fatal events to be
1 for every 3-6.6 million blood products administered. Febrile non-hemolytic reactions, while
uncomfortable for the patient, usually are not associated with severe morbidity or mortality and are
reported to occur in ~1 in 100 per products transfused depending upon the type of product. The lack of
consistent reporting of transfusion related adverse reactions demonstrates the need for national
surveillance to provide data that are more representative of actual events.
Incidents
In transfusion medicine most incidents do not result in harm to the patient. Studies have shown the risk of
erroneous or mistransfusion of red cell (RBC) units to be approximately 1 in 14,000 to 1 in 38,000 3. A
mistransfusion is failure to give the correct blood to the intended recipient and is a preventable human
error; in the worst consequence, this can result in major ABO incompatibility and patient illness or death.
Transfusion incidents can involve errors in more than one step of the process of getting the right blood to
the right patient. Identification of where in the process these incidents occur can provide information that
will help facilities improve their procedures and potentially prevent patient harm. Data collection for
incident reporting is intended to provide numbers of occurrences and types of incidents and near misses
where the error is discovered before the incorrect product reaches the patient.
Using the NHSN Hemovigilance Module
The Hemovigilance Module offers facilities to perform tracking, trending, and analysis of adverse
transfusion reactions as well as incidents that have led to mistransfusions, which may or may not have
led to an adverse reaction. Included in incident reporting is the reporting of a near-miss, which is an
incident that is discovered before an incorrect product reaches the patient. The purpose of the
Hemovigilance Module is to collect, analyze, and report information on blood transfusion-related adverse
events, including adverse reaction and incident reporting.
Definitions
†Adverse Event : An undesirable and unintended occurrence before, during, or after transfusion of blood
or blood components that may be related to the administration of the blood or blood component. It may be
the result of an incident and it may or may not result in a reaction in a recipient.
†Adverse Reaction : An undesirable response or effect in a patient temporally associated with the
administration of blood or blood component. It may be the result of an incident or an interaction between
a recipient and blood, which is a biologically active product.
†Incident : A case where the patient is transfused with a blood component which did not meet all the
requirements for a suitable transfusion for that patient, or that was intended for another patient. It thus
comprises transfusion errors and deviations from standard operating procedures or hospital policies that
have lead to mistransfusions. It may or may not lead to an adverse reaction.
†Near Miss : An error or deviation from standard procedures or policies that is discovered before the start
of a transfusion and that could have led to a wrongful transfusion or to a reaction in a recipient.
†Defined by the International Society of Blood Transfusion (ISBT).
For the purposes of surveillance, the NHSN Hemovigilance Module uses the following
definitions:
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Incident: Any error or accident that could lead to an adverse outcome affecting the safety, efficacy, or
quality of blood, blood components, or plasma derivatives; or the safety of transfusion recipients. This
includes errors, deviations from hospital standard operating procedures, and near misses.
High-priority Incident: Any incident that has high potential for wrongful transfusion in a recipient (for
example, wrong blood in tube) if the associated product were to be transfused. These include but are not
limited to sample labeling errors, patient identification errors, and special processing needs not indicated,
not done, misunderstood, misinterpreted, etc. The high-priority incidents are designated with a “+” in the
table in Appendix F.
Surveillance Methods
The Hemovigilance Module requires comprehensive, prospective, active and passive, patient-based
surveillance of patients throughout the transfusion process (from product receipt from supplier to
administration to the patient). The data collected will initially be used to produce crude event rates, but will
be expanded to risk-adjusted rates as more data is available.
Comprehensive
Priority-directed surveillance objectives are defined and focused on specific events, processes,
organisms, and/or patient populations. Comprehensive surveillance provides continuous monitoring of all
patients receiving transfusion for transfusion-related events. Hemovigilance will use comprehensive
surveillance methodology.
Prospective
Prospective surveillance involves on-going monitoring of patients for events while they are still
hospitalized. Retrospective surveillance is case-finding that is based on chart review after patient
discharge. Prospective surveillance is the recommended method of surveillance for hemovigilance.
Active and Passive
When performing active surveillance, trained personnel, such as staff in Hospital Blood Transfusion
Services, use standard definitions and a variety of data sources to identify events. Passive surveillance in
hemovigilance involves situations where personnel not trained to perform surveillance are required to
report blood transfusion adverse reactions and incidents to blood transfusion services as a part of their
job responsibilities. Hemovigilance will involve both active and passive surveillance methods.
Patient-based
Patient-based surveillance in hemovigilance involves monitoring individual patients for adverse reactions
of transfusion. Transfusion staff will be expected to provide guidance to patient care staff in identifying
and reporting blood transfusion adverse reactions. All reports of blood transfusion related events should
be investigated to ensure that reporting is as complete as possible. This may include reviewing patient
charts and discussing the event with caregivers.
Crude Rates vs. Risk-adjusted Rates
The last method we will discuss is the use of risk-adjusted or crude rates in analysis. Risk-adjusted rates
are controlled for variations in the distribution of major risk factors associated with an event’s occurrence.
Comparison of risk-adjusted rates between facilities is useful. Crude rates assume equal distribution of
risk factors for all events and are not useful for comparison. Rates in hemovigilance will be crude until
enough data have been collected for risk-adjustment
Surveillance Data
•	 Adverse Reaction Surveillance
Numerators:
o Adverse reactions that meet the definitive or probable case definition criteria each month.
o Deaths related to transfusion each month.
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Denominators:
o	 Numbers of units and/or aliquots of blood products transfused each month.
•	 Incident Surveillance
Numerators:
o	 Incidents reported each month.
o	 High priority incidents reported each month.
o	 Adverse reactions associated with incidents each month.
Denominators:
o	 Number of patient blood samples collected for type and screen or crossmatch each month.
Settings
Surveillance should be performed by hospital transfusion services and can be performed in any adult or
pediatric acute or chronic care facility where transfusion occurs, including patient care areas for
emergency, general medical, and surgical patients; obstetrics and gynecology; orthopedics, oncology,
and other chronic diseases; and any other patient care setting where transfusion services are provided.
When setting up your NHSN Facility, you will map each physical location in your facility to an NHSN
Facility Location. NHSN Facility Locations are shared across component. Therefore it is imperative that
you collaborate with your NHSN Facility Administrator to create and update NHSN Locations for use in
the Hemovigilance Module. More information on Location designation can be found at the NHSN website,
in the Hemovigilance Module training slides, and by accessing HELP when logged into NHSN. All
incidents and adverse reactions will be reported by location in NHSN. You must complete your Location
set up before reporting events.
Reporting Requirements
•	 Participating facilities are expected to provide at least 12 months of data when using the
 
Hemovigilance Module.
 
•	 Participating facilities are required to enter an Annual Facility Survey once per year.
•	 Participating facilities must enter a Monthly Reporting Plan for each month of surveillance.
Indicate on this form which method of Incident Reporting will be used each month.
•	 Participating facilities must report Monthly Reporting Denominators for each month of
 
surveillance.
 
•	 Participating facilities must report all blood or blood component transfusion-associated Adverse
Reactions (using NHSN Case Definitions) each month.
•	 Participating facilities must report all incidents that occur each month, but may choose from two
methods of incident reporting:
o	 Facilities may choose to enter a monthly summary report (counts only) of ALL incidents that
occur PLUS detailed reports for each of those that are designated as high-priority and
incidents associated with an Adverse Reaction regardless of incident code or priority
designation. This method is recommended for facilities that already utilize an electronic
reporting system for incident tracking.
o	 Facilities may choose to enter detailed reports for every single incident that occurs. This
method is recommended for facilities that do not otherwise electronically track or report
incidents and want to use NHSN for that purpose.
Data Collection Forms
There are six data collection forms used in the Hemovigilance Module. Instructions for completing each
form are found in the Hemovigilance Module Tables of Instruction posted on our website. All data are
reported to CDC using the NHSN web application. Paper forms are provided to aid participating facilities
in data collection.
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CDC 57.300 Hemovigilance Module Annual Facility Survey
Participating facilities must enter a Hemovigilance Module Annual Facility Survey at the time that they
enroll or activate the module and at the beginning of each calendar year thereafter. The Hemovigilance
Module Annual Facility Survey is used by CDC to classify facilities for appropriate comparisons in
aggregate data analyses and to learn more about common practices among Transfusion Departments.
The data collected in the Hemovigilance Module Annual Facility Survey covers the previous calendar
year. For example, if you are enrolling in NHSN for the first time in October of 2010, you will collect
information for January 2009-December 2009 in your first Hemovigilance Module Annual Facility Survey.
CDC 57.301 Hemovigilance Module Monthly Reporting Plan
A Monthly Reporting Plan must be entered for each month before data can be entered into the system.
Plans can be copied forward for all the months of the same calendar year. The Monthly Reporting Plan is
used to inform CDC of the facility’s chosen method of reporting Incidents each month.
CDC 57.302 Hemovigilance Module Monthly Incident Summary
The Hemovigilance Module Monthly Incident Summary is required if the facility chooses summary incident
reporting as the reporting method in the Monthly Reporting Plan. Report any incident for which an incident
report has been filed in blood transfusion services. Detailed reports must also be completed for all High-
priority incidents that occur and for incidents that are associated with a reported Adverse Reaction. High
priority incidents are indicated by a “+” next to the code on the form. Near misses should be documented
as robustly as incidents that result in harm to the patient. In addition, detailed incident reports can be filed
for any incident where additional information is desired, regardless of the method of reporting used. When
completing this form, ALL incidents that occur should be counted, including those for which a detailed
report is also entered. Monthly Incident Summaries should be entered within 30 days of the end of each
month.
CDC 57.303 Hemovigilance Module Monthly Reporting Denominators
Facilities must report the total numbers of units and/or aliquots of specified blood products transfused
each month. When reporting aliquots, the units from which they are made should NOT be counted as a
transfused unit. The total number of patient samples collected is also reported on this form. Monthly
Reporting Denominators should be entered within 30 days of the end of each month.
CDC 57.304 Hemovigilance Module Adverse Reaction
All transfusion-associated Adverse Reactions are reported using the Hemovigilance Adverse Reaction
form. Report only one Adverse Reaction per form. If a patient experiences more than one adverse
reaction during or following the same transfusion episode, complete a separate form for each reaction. Be
sure that the definition of one reaction is not included in the definition of the other. For example, a
hypotensive transfusion reaction should only be reported if hypotension is not included in the symptom
description of another, more specific reaction experienced by the patient during the same transfusion
episode. Adverse reactions considered to be transfusion-associated are those for which imputability is
determined to be definite, probable, or possible. Adverse reactions for which imputability is doubtful or
ruled out should not be routinely reported. The doubtful and ruled out categories should only be used
when an adverse reaction that was reported in the system was later determined not to be transfusion-
related based on new or additional information. Adverse reaction reports should be entered into NHSN
after the investigation of the reaction has been completed and imputability has been determined to the
extent possible. Ideally, reports will be entered within 30 days of the month that the reaction occurred.
However, new information can be entered at any time. Adverse Reaction Case Definitions are found in
Appendix A.
Please Note: Reporting of adverse reactions into the NHSN hemovigilance surveillance system does
NOT take the place of current reporting requirements for blood transfusion-associated adverse events to
Food and Drug Administration (FDA). Hospitals and transfusion services should immediately report
complications that may be related to the blood donor or to the manufacture of the blood components to
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the collection facility (Code of Federal Regulations. Title 21 CFR 606.170(a), 2006) and are required to
report suspected transfusion-related fatalities directly to FDA (Code of Federal Regulations Title 21 CFR
606.170(b), 2006).
CDC 57.305 Hemovigilance Module Incident
The Hemovigilance Module Incident form should be completed for every incident that occurs if “detailed
reporting of all incidents” is documented on the Monthly Reporting Plan. Report any incident for which an
incident report has been filed in blood transfusion services. Report only one incident per form. “Near
misses” should be documented as robustly as incidents negative outcomes. All reports should be entered
within 30 days of the month of the “Date of Discovery” for the event.
If the “summary incident” reporting option is chosen on your Monthly Reporting plan, the Hemovigilance
Module Incident form should be completed for all high-priority incidents, all incidents that are related to an
adverse reaction, and any additional incident that you would like to collect detailed information form. All
incidents that occur should be documented on the Monthly Incident Summary form.
Data Analysis and Reports
Facilities will have the ability to generate a number of predetermined reports in NHSN. In addition, custom
line lists and reports can be created by selecting variables of interest within the application. Once
sufficient data has been collected from participating facilities and CDC has published aggregate analyses
of the data, comparative values will be included in the facility-level reporting options.
Standard facility-level reports include:
•	 Line lists
•	 Adverse Reactions, including occurrence details, product information, and patient outcomes
•	 Incidents, including occurrence details, incident outcomes, and investigation outcomes
•	 High-Priority Incidents, including occurrence details, incident outcomes, and investigation
 
outcomes
 
•	 Frequency reports
•	 Adverse Reactions by product(s) transfused
•	 Fatalities by adverse reaction
•	 Fatalities by product(s) transfused
•	 Incidents as a function of total incidents reported for a selected time period
•	 Incidents by number of samples collected
•	 Types and numbers of units/aliquots transfused by selected time period
•	 Adverse Reaction symptom report by adverse reaction reported
•	 ABO incompatibility report by adverse reaction reported
REFERENCES
1.	 AABB Survey. The 2005 nationwide blood collection and utilization survey report. Available at:
http://www.aabb.org/apps/docs/05nbcusrpt.pdf.
2.	 Eder AF, Chambers L. Noninfectious complications of blood transfusion. Arch Pathol Lab Med.
2007; 131: 708-718.
3.	 Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York State: an
analysis of 10 years’ experience. Transfusion. 2000; 40: 1207-1213.
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Appendix A. Adverse Reaction Case Definition Criteria
Allergic reaction: The result of an interaction of an allergen with preformed antibodies. In some
instances, infusion of antibodies from an atopic donor may also be involved. It may present with only
mucocutaneous signs and symptoms.
Case Definition Criteria Severity Imputability
Signs/Symptoms Laboratory/Radiology
Definitive:
≥ 2 of the following
occurring during or
within 4 hours of the
transfusion:
• Maculopapular
rash with or
without pruritus
• Urticaria
• Pruritis
• Generalized
flushing
• Localized
angioedema
• Edema of lips,
tongue and uvula
• Erythema and
edema of the
periorbital area
• Conjunctival
edema
• Respiratory
distress;
bronchospasm
• Hypotension
Probable:
N/A
Possible:
N/A
Definitive:
N/A
Probable:
N/A
Possible:
N/A
Grade 1:
No immediate risk to the life of the
patient
AND
Responds quickly to symptomatic
treatment.
Grade 2–4:
Involves respiratory and/or
cardiovascular systems and
presents like an anaphylactic
reaction. There is anaphylaxis
when, in addition to
mucocutaneous symptoms, there
are airway symptoms or
hypotension or associated
symptoms like hypotonia and,
syncope. The respiratory signs
and symptoms may be laryngeal
(tightness in the throat, dysphagia,
dysphonia, hoarseness, stridor) or
pulmonary (dyspnea, cough,
wheezing, bronchospasm,
hypoxemia). Such a reaction
usually occurs during or very soon
after transfusion.
For the purpose of classification
this type of allergic reaction
would be graded as 2) severe, 3)
life-threatening, or 4) death,
depending on the course and
outcome of the reaction.
Definite:
No other evidence of
environmental, drug or
dietary risks
AND
Occurs during or within 2
hours after transfusion.
Probable:
Other potential causes in
an individual with known
susceptibility (atopic;
previous allergic
reactions to transfusions).
AND
Occurs during or within 2
hours after transfusion.
Possible:
Other likely causes such
as medication or
exposures but transfusion
cannot be ruled out,
usually a first reaction of
this sort
AND
Occurs 2-4 hours after
transfusion.
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NHSN Biovigilance Component
Protocol
Acute hemolytic transfusion reaction (AHTR): Rapid destruction of red blood cells during, immediately
after, or within 24 hours of a transfusion. Clinical and laboratory signs of hemolysis are present. No single
criterion exists to definitively diagnose this rare disorder. See Appendix D for common antibodies
associated with AHTR.
Case Definition Criteria Severity Imputability
Signs/Symptoms Laboratory/Radiology
Definitive: Definitive: Use severity grades Definite:
Occurs during, immediately Positive direct antiglobulin as defined in Occurs during,
after, or within 24 hours of test for anti-IgG or anti-C3 Appendix C. immediately after or
transfusion with ANY of the AND within 24 hours of
following: Positive elution test with transfusion.
• Chills/rigors alloantibody present on the AND EITHER
• Fever transfused red blood cells There is known ABO
• Back/flank pain AND or other allotypic RBC
• Hypotension ≥2 of the following: antigen incompatibility
• Hemoglobinuria during • Elevated LDH OR
or shortly after • Elevated bilirubin Serologic work-up
transfusion • Low haptoglobin consistent with AHTR
• Epistaxis • Hemoglobinuria and no other cause of
• Oliguria/anuria • Low fibrinogen acute hemolysis.
• Renal failure
• Disseminated
• Elevated plasma
hemoglobin Probable:Occurs during,intravascular
coagulation (DIC)
• Pain and/or oozing at IV
site
AND EITHER
Probable:
Incomplete laboratory
results to meet definitive
case definition criterion.
immediately after or
within 24 hours of
transfusion but no
serologic evidence of
AHTRABO incompatibility or
other allotypic RBC
antigen incompatibility
Possible:
N/A
AND
Blood bank testing may
show abnormal results
but AHTR may also be
OR due to erythrocyte auto-
antibodies in the
Clerical check indicates recipient.
that the patient’s name
and blood group on the Possible:
blood unit are different Occurs during,
than the recipient’s name immediately after or
and blood group. within 24 hours of
transfusion but there is
Probable: evidence of non-
Any combination of clinical immune contributing
features as above factors such as
hemolysis-inducing
Possible: mechanical factors (e.g.
N/A malfunction of a pump,
blood warmer, use of
hypotonic solutions,
etc.).
Page 12 of 30
 
July 2010
 
   
 
    
  
             
                 
        
 
     
  
 
   
   
    
   
 
   
   
  
  
  
   
  
  
 
  
 
    
    
  
 
 
    
 
 
 
 
  
   
  
  
    
    
    
 
     
    
  
   
    
      
  
 
  
   
 
    
     
    
      
  
 
 
     
     
   
 
 
 
  
   
   
 
   
    
 
   
     
 
 
  
   
    
    
    
 
    
   
 
 
   
     
  
 
    
    
 
   
  
 
 
 
NHSN Biovigilance Component
Protocol
Delayed hemolytic transfusion reaction (DHTR): The recipient develops antibodies to RBC antigen(s)
between 24 hours and 28 days after a transfusion. Clinical signs of hemolysis are usually present. See
Appendix D for common antibodies associated with DHTR.
Case Definition Criteria Severity Imputability
Signs/Symptoms Laboratory/Radiology
Definitive:
Patient may be
asymptomatic or have
similar to, but milder
symptoms than AHTR.
Examples of milder
symptoms include:
• Chills/rigors
• Fever
• Jaundice
• Back/flank pain
• Hypotension
• Hemoglobinuria/
hematuria
• Oliguria/anuria.
NOTE: These are NOT
required to meet definitive
case criteria.
Probable:
Same as definitive case
criteria.
Possible:
N/A
Definitive:
Positive direct antiglobulin
(Coombs) test
AND EITHER
Positive elution test with
alloantibody present on the
transfused red blood cells
OR
Newly identified red blood cell
alloantibody in recipient serum
AND EITHER
Inadequate rise of post-
transfusion hemoglobin level or
rapid fall in hemoglobin back to
pre-transfusion levels
OR
Otherwise unexplained
appearance of spherocytes.
NOTE: If performed, post
transfusion increases in LDH and
bilirubin levels that subsequently
fall back to baseline in the
following days.
Probable:
Newly identified red blood cell
alloantibody but does not meet
definitive laboratory criteria.
Possible:
N/A
Use severity
grades as defined
in Appendix C.
Definite:
Newly identified red
blood cell alloantibody
AND
Occurs between 24
hours and 28 days after
transfusion
AND
Positive direct
antiglobulin test with
identification of a new
antibody either in the
serum or eluate
AND
No other explanation for
drop in hemoglobin.
Probable:
Occurs between 24
hours and 28 days after
transfusion.
AND
No other explanation for
drop in hemoglobin.
AND
No confirmation on
serologic testing.
Possible:
N/A
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NHSN Biovigilance Component
Protocol
Delayed serologic transfusion reaction (DSTR): Demonstration of new, clinically significant
alloantibodies against red blood cells between 24 hours and 28 days after a transfusion despite an
adequate, maintained hemoglobin response. See Appendix D for common antibodies associated with
DSTR.
Case Definition Criteria Severity Imputability
Signs/Symptoms Laboratory/Radiology
Definitive:
No clinical or laboratory
signs of hemolysis.
Probable:
N/A
Possible:
N/A
Definitive:
Demonstration of new,
clinically significant
antibodies against red blood
cells between 24 hours and
28 days after a transfusion
that were not present in the
pre-transfusion specimen
BY EITHER
Positive direct antiglobulin
(Coombs) test
OR
Positive antibody screen
with newly identified RBC
alloantibody.
Probable:
N/A
Possible:
N/A
Use severity grades
as defined in
Appendix C.
Definite:
Occurs 24 hours to 28
days after the transfusion
AND EITHER
Recent RBC
transfusion with
subsequent formation
of newly identified RBC
alloantibody
OR
Positive direct
antiglobulin test.
Probable:
N/A
Possible:
N/A
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NHSN Biovigilance Component
Protocol
Hypotensive transfusion reaction: A drop in systolic and/or diastolic blood pressure occurring during or
within one hour of completing transfusion.
Case Definition Criteria Severity Imputability
Signs/Symptoms Laboratory/Radiology
Definitive:
ALL OF THE FOLLOWING:
• Hypotension
- Adults (≥18 years of age): Drop
in systolic and/or diastolic blood
pressure of >30 mm Hg.
- Infants, children (≥1 year old) and
adolescents (<18 years of age):
>25% drop in systolic BP (e.g.,
drop in baseline systolic BP of
120mm/Hg to below 90mm/Hg).
- Neonates, small infants < 1 year
of age OR any age and <12 kg
body weight: >25% drop in
baseline value using whichever
measurement being recorded
(e.g., mean BP).
• Occurs within 15 minutes after the
start of the transfusion
• Responds rapidly (within 10
minutes) to cessation of transfusion
and supportive treatment
• All other categories of adverse
reactions presenting with
hypotension are excluded.
Note 1: Other symptoms, such as
facial flushing, dyspnea, or abdominal
cramps may occur but usually
hypotension is the sole manifestation.
Note 2: If the patient meets the criteria
for another, more specific adverse
transfusion reaction where hypotension
is a symptom of that reaction, the more
specific adverse reaction should be
reported.
Probable:
Same as definitive criteria
EXCEPT:
Onset is greater than 15 minutes after
start of transfusion
OR
The patient does not respond within
10 minutes to cessation of transfusion
and supportive treatment.
Definitive:
N/A
Probable:
N/A
Possible:
N/A
Grade 1:
The recipient required
no more than
discontinuation of
transfusion and
symptom management
AND
No long-term morbidity
resulted from the
reaction.
Grade 2:
The recipient required
in-patient
hospitalization or
prolongation of
hospitalization due to
hypotension or
hypotension led
directly to long-term
morbidity (e.g., brain
damage)
AND
Vasopressors were not
required.
Grade 3:
The recipient required
vasopressors.
Grade 4:
The recipient died as a
result of the reaction or
as a result of treatment
directly related to
resolving symptoms of
the hypotensive
transfusion reaction.
Definite:
Meets the
definitive protocol
criterion
AND
The patient has no
other conditions
that could explain
hypotension.
Probable:
Other conditions
that could explain
hypotension are
unlikely but not
fully excluded.
Possible:
Other conditions
that could readily
explain
hypotension are
present.
Possible:
Same as definitive criteria EXCEPT:
Other conditions are present or were
present before the transfusion that
could explain hypotension.
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NHSN Biovigilance Component
Protocol
Febrile non-hemolytic transfusion reaction (FNHTR): Fever and/or chills without hemolysis occurring
in the patient up to 4 hours during and after transfusion. If transfusion-related, the most common cause is
a reaction to passively transfused cytokines or a reaction of recipient antibodies and leukocytes in the
blood product.
Case Definition Criteria Severity Imputability
Signs/Symptoms Laboratory/Radiology
Definitive:
Occurs during or within 4
hours of transfusion
AND EITHER
Fever (≥38oC oral or
equivalent and a change of
≥1oC from pre-transfusion
value)
OR
Chills/rigors are present.
NOTE: FNHTR can be
present in absence of fever if
chills or rigors occur.
Probable:
N/A
Possible:
N/A
IF PERFORMED
(Not required to meet
definitive criteria):
• Negative culture of
residual component
• Negative post-
transfusion patient
blood culture
• Lab findings not
consistent with
acute hemolysis as
cause of fever.
Use severity grades
as defined in
Appendix C.
Definite:
Meets definitive protocol
criterion
AND
Patient has no other
conditions that could explain
symptoms.
Probable:
Other conditions that could
explain fever/chills are
unlikely but not fully
excluded.
Possible:
Other conditions are present
or were present before the
transfusion that could
explain the symptoms.
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NHSN Biovigilance Component
Protocol
Post transfusion purpura (PTP): Thrombocytopenia usually arising 5-12 days following transfusion of
cellular blood components with findings of antibodies in the patient directed against the Human Platelet
Antigen (HPA) system.
Case Definition Criteria Severity Imputability
Signs/Symptoms Laboratory/Radiology
Definitive:
Thrombocytopenia (decrease to
<20% of pre-transfusion count)
AND
Occurs 5-12 days post-
transfusion.
Probable:
Thrombocytopenia (decrease to
<20% of pre-transfusion count)
but 5-12 days post-transfusion
timeframe not met
OR
Thrombocytopenia (decrease to
<20% of pre-transfusion count)
with competing explanations
OR
Drop in platelets between 20%
and 80% of pre-transfusion
count.
Possible:
Clinical and laboratory
presentation meet definitive or
probable criteria but alternate
explanations more likely
OR
Clinical presentation meets
definitive or probable criteria but
HPA antibodies not tested or
negative.
Definitive:
Alloantibodies in the
patient directed against
HPA-1a or other platelet
specific antigen
detected at or after
development of
reaction.
Probable:
Alloantibodies in the
patient directed against
HPA-1a or other platelet
specific antigen
detected at or after
development of
reaction.
Possible:
HPA antibodies not
tested or negative.
Use severity grades
as defined in
Appendix C.
Definite:
Meets definitive OR
probable case definition
criterion.
Probable:
N/A
Possible:
Meets possible case
definition criterion.
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NHSN Biovigilance Component
Protocol
Transfusion associated circulatory overload (TACO): Infusion volume that cannot be effectively
processed by the recipient either due to high infusion rate and/or volume or an underlying cardiac or
pulmonary pathology.
Case Definition Criteria Severity Imputability
Signs/Symptoms Laboratory/Radiology
Definitive:
New onset or exacerbation of
≥ 3 of the following within 6
hours of transfusion:
• Acute respiratory distress
(dyspnea, orthopnea,
cough)
• Evidence of positive fluid
balance
• Elevated brain natriuretic
peptide (BNP)
• Radiographic evidence of
pulmonary edema
• Evidence of left heart
failure
• Elevated central venous
pressure (CVP).
Probable:
N/A
Possible:
N/A
Definitive:
N/A
Probable:
N/A
Possible:
N/A
Use severity
grades as defined
in Appendix C.
Definite:
Meets definitive case
definition criterion and no
other cause of volume
overload are possible.
Probable:
Meets definitive case
definition
AND
Transfusion is a likely
contributor to volume
overload, but the patient
received other fluids as well.
Possible:
Meets definitive case
definition criterion but the
patient has a history of pre­
existing cardiac insufficiency.
NOTE: Imputability should
not be classified higher than
possible if the patient has a
history of pre-existing cardiac
insufficiency.
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NHSN Biovigilance Component
Protocol
Transfusion associated dyspnea (TAD): Respiratory distress within 24 hours of transfusion that does
not meet the criteria of TRALI, TACO, or allergic reaction. Respiratory distress should not otherwise be
explained by a patient’s underlying or pre-existing medical condition.
Case Definition Criteria Severity Imputability
Signs/Symptoms Laboratory/Radiology
Definitive:
Acute respiratory distress
AND
Occurs within 24 hours of
transfusion
AND
TRALI, TACO, allergic reaction
and other underlying medical
conditions ruled out.
Probable:
N/A
Possible:
N/A
Definitive:
N/A
Probable:
N/A
Possible:
N/A
Use severity grades
as defined in
Appendix C.
Use imputability
criteria as defined in
Appendix C.
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NHSN Biovigilance Component
Protocol
Transfusion associated graft vs. host disease (TAGVHD): The introduction of immunocompetent
lymphocytes into susceptible hosts. The allogeneic lymphocytes engraft, proliferate and destroy host
cells.
Case Definition Criteria Severity Imputability
Signs/Symptoms Laboratory/Radiology
Definitive:
A clinical syndrome occurring
from 2 days to 6 weeks
following transfusion
characterized by symptoms
of:
• Fever
• Characteristic rash:
Erythematous,
maculopapular eruption
centrally that spreads to
extremities and may, in
severe cases, progress
to generalized
erythroderma and
hemorrhagic bullous
formation.
• Hepatomegaly
• Diarrhea
Probable:
Clinical presentation
consistent with TAGVHD
described above.
Possible:
Clinical presentation
consistent with TAGVHD
described above.
Definitive:
Liver dysfunction, i.e.,
elevated ALT, AST, Alkaline
phosphatase, and elevated
bilirubin
AND
Pancytopenia
AND
WBC chimerism in the
absence of alternative
diagnoses
AND
Characteristic histological
appearance of skin biopsy
or liver biopsy.
NOTE: If performed,
marrow study shows
hypoplasia, aplastic
anemia, or marked
hypocellularity with a
lymphohistiocytic infiltrate.
Probable:
Meets definitive laboratory
criteria
EXCEPT
Biopsy negative or not
done.
Possible:
Meets definitive criteria
EXCEPT
Chimerism not present or
not done.
Grade 1:
N/A
Grade 2:
Patient had marked
symptoms and
responded to
treatment.
Grade 3:
Patient had severe
symptoms and alive
due to treatment (e.g.,
immunosuppression).
Grade 4:
Patient died from
TAGVHD.
Definite:
Meets definitive case
definition criterion and
related to blood donor,
i.e. there are matching
chimeric alleles in the
donor and recipient.
Probable:
Presentation consistent
with TAGVHD; however,
chimerism demonstrated
in recipient but matching
alleles could not be
tested in the donor.
Possible:
Presentation consistent
with TAGVHD though
alternative explanations
are likely and TAGVHD
cannot be confirmed, as
with negative chimerism
studies or in the case of
allogeneic solid organ
transplantation.
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NHSN Biovigilance Component
Protocol
Transfusion-related acute lung injury (TRALI): Acute hypoxemia with PaO2/fraction of inspired oxygen
[FIO2] ratio of 300 mm Hg or less combined and chest x-ray showing bilateral infiltrates in the absence of
left atrial hypertension (i.e., circulatory overload). Onset of TRALI is abrupt in association with transfusion.
Case Definition Criteria Severity Imputability
Signs/Symptoms Laboratory/Radiology
Definitive:
NO evidence of acute lung injury
(ALI) prior to transfusion
AND
ALI onset during or within 6 hours of
transfusion
AND
Hypoxemia defined by any of these
methods:
• PaO2 / FiO2 ≤ 300 mm Hg
• Oxygen saturation is < 90% on
room air
• Other clinical evidence
AND
No evidence of left atrial
hypertension (i.e. circulatory
overload)
AND
No temporal relationship to an
alternative risk factor for ALI during
or within 6 hours of completion of
transfusion.
Probable:
N/A
Possible:
Same as definitive EXCEPT there is
a temporal relationship to one of the
following alternate risk factors:
• Direct Lung Injury
• Aspiration
• Pneumonia
• Toxic inhalation
• Lung contusion
• Near drowning
• Indirect Lung Injury
• Severe sepsis
• Shock
• Multiple trauma
• Burn injury
• Acute pancreatitis
• Cardiopulmonary bypass
• Drug overdose
Definitive:
Bilateral infiltrates on
chest radiograph
Probable:
N/A
Possible:
N/A
Use severity
grades as defined
in Appendix C.
Definite:
Meets definitive case
definition criterion.
Probable:
N/A
Possible:
Meets possible case
definition criterion.
Page 21 of 30
 
July 2010
 
   
 
    
  
            
      
 
       
             
                 
    
    
  
  
  
 
 
  
  
 
 
 
 
  
 
  
  
 
   
  
  
  
   
  
   
  
   
    
   
    
   
    
   
  
   
   
 
 
  
 
 
 
      
               
              
            
               
              
        
               
               
     
              
           
    
          
        
             
   
                
     
        
          
           
 
              
           
            
                
  
          
NHSN Biovigilance Component
Protocol
Transfusion-transmitted infection: A bacteria, parasite, virus, or other potential pathogen transmitted
in donated blood to transfusion recipient.
Pathogens of well-documented importance in blood safety.
These pathogens have public health significance for hemovigilance, are well-documented blood stream pathogens
and/or, are routinely screened for in blood donors. All infectious organisms are available from the full drop-down
pathogen list in NHSN.
Bacterial Viral Parasitic Other
Escherichia coli
Klebsiella oxytoca
Klebsiella pneumoniae
Pseudomonas
aeruginosa
Serratia marcescens
Staphylococcus aureus
Staphylococcus
epidermidis
Staphylococcus
lugdunensis
Syphilis (Treponema
pallidum)
Yersinia enterocolitica
Cytomegalovirus (CMV)
Enterovirus
Epstein Barr (EBV)
Hepatitis A
Hepatitis B
Hepatitis C
Human Immunodeficiency Virus
1 (HIV-1)
Human Immunodeficiency Virus
2 (HIV-2)
Human Parvovirus B-19
Human T-Cell Lymphotropic (or,
leukemia) Virus-1 (HTLV-1)
Human T-Cell Lymphotropic (or,
leukemia) Virus-2 (HTLV-2)
West Nile Virus (Flaviviridae)
Babesiosis (Babesia spp.)
Chagas disease
(Trypanosoma cruzi)
Malaria (Plasmodium spp.)
Creutzfeldt-Jakob
Disease, Variant
(vCJD)
Investigation triggers for infections potentially transfusion-transmitted:
1.	 Identification by testing (e.g., gram stain, other smear/staining, culture, or other method) of an
unexpected bacterial, mycobacterial, or fungal organism in a recipient within the time period from
exposure (i.e., transfusion) to onset of infection appropriate for the suspected pathogen.
2.	 Identification of an unexpected virus in the recipient by testing (e.g., culture, direct fluorescent
antibody or polymerase chain reaction) within the time period from exposure (i.e., transfusion) to
onset of infection appropriate for the suspected virus.
3.	 Identification of an unexpected parasite in the recipient by blood smear, histopathology or stool
testing for ova/parasites within the time period from exposure (i.e., transfusion) to onset of infection
appropriate for the suspected parasite.
4.	 Any of the above laboratory findings in the recipient unit upon residual testing.
5.	 Unexplained clinical events occurring after transfusion that are consistent with transfusion-

transmitted infection, such as:
 
a.	 Encephalitis, meningitis, or other unexplained central nervous system abnormalities.
b.	 Sepsis with or without multi-organ system dysfunction.
c.	 Hemolytic anemia and/or fever (e.g., in cases of transfusion-associated babesiosis or malaria).
d.	 Recipient death.
6.	 For pathogens routinely screened in the blood donor, any infection in the recipient occurring within
6 months after transfusion if:
a.	 The index donation testing was negative but
b.	 The donor was subsequently found to be infected, and
c.	 The recipient had no pre-transfusion history of the same infection.
For a decision on imputability, consider various types of evidence such as the following:
1.	 Evidence of contamination of the recipient unit upon residual testing.
2.	 Pre- and post- transfusion infection status (e.g., seroconversion) in the recipient.
3.	 Evidence of other recipients with infection from the same organism who received blood from the
same donor.
4.	 Evidence of the donor infection with the same organism.
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NHSN Biovigilance Component
Protocol
Case Definition Criteria Severity Imputability
Signs/Symptoms Laboratory/Radiology
Definitive:
N/A
Probable:
N/A
Possible:
N/A
NOTE: An
investigation can
be initiated based
on clinical events
occurring after
transfusion that
are consistent with
transfusion-
transmitted
infection.
However; there
must be laboratory
evidence of the
suspected
pathogen in the
transfusion
recipient to call an
adverse reaction a
transfusion-
transmitted
infection.
Definitive:
Laboratory evidence of
the suspected pathogen
in the transfusion
recipient.
Probable:
N/A
Possible:
N/A
Use
severity
grades as
defined in
Appendix
C.
Definite:
An investigation trigger with laboratory evidence of
the suspected organism in the recipient
AND
Evidence that the recipient was not infected with this
organism prior to transfusion
AND
Laboratory evidence of infection with the same
organism in the donor
AND
Laboratory evidence of infection with the same
organism in any other recipients from the same
donor as the initial case recipient
OR
Laboratory evidence of the infection with the same
organism in the recipient unit (or retained segment)
or co-component from the original donation.
Probable:
An investigation trigger with laboratory evidence of
the suspected organism in the recipient
Plus any two of the following:
Evidence that the recipient was not infected with
this organism prior to transfusion
OR
Laboratory evidence of infection with the same
organism in other recipients (if any) from the same
donor as the initial case recipient
OR
Laboratory evidence of infection with the same
organism the donor
OR
Laboratory evidence of infection with the same
organism in the recipient unit (or retained segment)
or co-component from the original donation.
Possible:
An investigation is triggered, but information essential
for confirming or ruling out a case is missing, not
available, or cannot be obtained
AND
Case fails to meet definition for definite, probable or
ruled out.
Doubtful or Ruled Out:
(Do not file a report with NHSN)
Laboratory evidence that the donor is negative
for infection.
OR
Laboratory evidence that the recipient had
infection with this organism prior to transfusion.
NOTE: For bacterial cases, identification of the
organism in the unit upon residual testing is
equivalent to laboratory evidence of the same
organism in the donor.
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NHSN Biovigilance Component
Protocol
Appendix B. Adverse Reaction Clinical and Laboratory Definitions
Blood pressure decrease:
•	 Adults (≥ 18 years of age): Drop in systolic and/or diastolic blood pressure (BP) of > 30 mm Hg.
•	 Infants, children (≥ 1 year old), & adolescents (<18 years of age): > 25% drop in systolic BP (e.g., drop in
baseline systolic BP of 120mm/Hg to below 90mm/Hg).
•	 Neonates & small infants (< 1 year of age OR any age and < 12 kg body weight): > 25% drop in baseline
value in whatever measurement is being recorded (e.g,, mean BP).
Bronchospasm (wheezing): A contraction of smooth muscle in the walls of the bronchi and bronchioles,
causing acute narrowing and obstruction of the respiratory airway. This constriction can result in a rasp or
whistling sound while breathing.
Chills/rigors: A feeling of cold with shivering or shaking and pallor, occurring during or within 4 hours of
transfusion.
Disseminated intravascular coagulation (DIC): Bleeding disorder characterized by reduction in the factors
involved in blood clotting due to their use in widespread clotting within the vessels. The intravascular clotting
ultimately produces hemorrhage because of rapid consumption of clotting factors.
Edema: Swelling of soft tissues as a result of excessive fluid accumulation.
Fever: An increase of ≥ 1°C in temperature over the pre-transfusion temperature during or within 4 hours of
the completion of the transfusion.
Hematuria: Presence of blood or red blood cells in the urine.
Hemoglobinemia: The presence of free hemoglobin in the blood plasma.
Hemoglobinuria: Presence of free hemoglobin in the urine.
Hypoxemia: Abnormal deficiency in the concentration of oxygen in arterial blood. PaO2 / FiO2 ≤ 300 mm Hg
OR oxygen saturation is < 90% on room air.
Jaundice: New onset or worsening of yellow discoloration (icterus) of the skin or sclera (scleral icterus)
secondary to an increased level of bilirubin.
Oliguria: New onset of decreased urinary output within 72 hours of the identification of the blood transfusion
reaction (< 500 cc output per 24 hours).
Other rash: Other (non-urticarial) skin rash experienced during or within 4 hours of the completion of
transfusion.
Pain (abdominal, back, flank, infusion site): Pain experienced at any site during or within 4 hours of
completion of transfusion.
Pruritis: Itching
Shock: A drop in blood pressure accompanied by a drop in cardiac output including rapid heart rate (increase
to ≥ 100 beats per minute), rapid breathing, cutaneous vasoconstriction, pallor, sweating, decreased or scanty
urine production, agitation and/or loss of consciousness that required fluid resuscitation, with or without
inotropic support.
Shortness of breath (dyspnea): New onset or significant worsening of shortness of breath; or a significant
increase in respiratory rate (with or without hypoxemia) during or within 24 hours of the completion of
transfusion.
Urticaria (hives): Raised red spots with or without itching, or generalized itching without redness during or
within 4 hours of the completion of the transfusion.
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Appendix C. Adverse Reaction Severity and Imputability Definitions
Severity
Grade 1: Non-Severe
Medical intervention (e.g. symptomatic treatment) is required but lack of such would not result in
permanent damage or impairment of a bodily function.
Grade 2: Severe
Inpatient hospitalization or prolongation of hospitalization is directly attributable to the adverse
reaction, persistent or significant disability or incapacity of the patient occurs as a result of the
reaction, or a medical or surgical intervention is necessary to preclude permanent damage or
impairment of a body function.
Grade 3: Life-threatening
Major intervention required following the transfusion (e.g. vasopressors, intubation, transfer to
intensive care) to prevent death.
Grade 4: Death
The recipient died as a result of the adverse transfusion reaction.
Note: Grade 4 should be used only if death is possibly, probably or definitely related to
transfusion. If the patient died of a cause other than the transfusion, the severity of the reaction
should be graded as 1, 2 or 3, as appropriate given the clinical circumstances related to the reaction.
Imputability
Once the investigation of the adverse transfusion reaction is completed, this is the assessment of the the
relationship between the transfusion and the adverse reaction.
Definite: Conclusive evidence exists that the adverse reaction can be attributed to the transfusion.
Probable: Evidence is clearly in favor of attributing the adverse reaction to the transfusion.
Possible: Evidence is indeterminate for attributing the adverse reaction to the transfusion or an
alternate cause.
*Doubtful: Evidence is clearly in favor of attributing the adverse reaction to a cause other than the
transfusion.
*Ruled Out: Conclusive evidence beyond reasonable doubt that the adverse event can be attributed
to a cause other than the transfusion.
Not Determined: The relationship between the adverse reaction and the transfusion is unknown or
not stated.
*Adverse reactions for which imputability is doubtful or ruled out should not be routinely reported. The
only time these categories can be used is when a reaction was initially thought to be transfusion-related
but additonal information revealed a non-transfusion related cause.
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Appendix D. Antibodies Associated with Hemolytic Transfusion Reactions

Anti-A
Anti-B
Anti-A,B
Anti-C
Anti-D
Anti-E
Anti-c
Anti-e
Anti-K
Anti-k
Anti-Jka 
Anti-Jkb 
Anti-S
Anti-Fya
Anti-Fyb 
Anti-M
Other
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Appendix E.  NHSN Occupation Codes 
 
Laboratory Additional Occupation Types 
IVT IVT Team Staff ATT Attendant/Orderly 
MLT Medical Laboratory Technician CSS Central Supply 
MTE Medical Technologist CSW Counselor/Social Worker 
PHL Phlebotomist/IV Team DIT Dietician  
Physician DNA Dental Assistant/Technician 
LPN Licensed Practical Nurse DNH Dental Hygienist 
CNA Nurse Anesthetist DNO Other Dental Worker 
CNM Certified Nurse Midwife  DNT Dentist 
NUA Nursing Assistant DST Dental Student 
NUP Nurse Practitioner FOS Food Service 
RNU Registered Nurse HSK Housekeeper 
Nursing ICP Infection Control Professional 
FEL Fellow LAU Laundry Staff 
MST Medical Student MNT Maintenance/Engineering 
PHY Attending Physician MOR Morgue Technician 
RES Intern/Resident  OAS Other Ancillary Staff 
Technicians OFR Other First Responder 
EMT EMT/Paramedic OH Occupational Health Professional 
HEM Hemodialysis Technician OMS Other Medical Staff 
ORS OR/Surgery Technician OTH Other 
PCT Patient Care Technician OTT Other Technician/Therapist 
Other Personnel PAS Physician Assistant 
CLA Clerical/Administrative PHA Pharmacist 
TRA Transport/Messenger/Porter PHW Public Health Worker 
  PLT Physical Therapist 
  PSY Psychiatric Technician 
  RCH Researcher 
  RDT Radiologic Technologist 
  RTT Respiratory Therapist/Technician 
  STU Other Student 
  VOL Volunteer 
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Appendix F. NHSN Incident Codes (Based on MERS-TM & TESS)
Product Check-In
(Products Received from Outside Source)
PC 00 Detail not specified
PC 01 Data entry incomplete/not
performed/incorrect
PC 02 Shipment incomplete/incorrect
PC 03 Product and paperwork do not match
PC 04 Shipped under inappropriate conditions
PC 05 Inappropriate return to inventory
PC 06 Product confirmation
PC 07 Administrative check (2nd check)
Product/Test Request
(Clinical Service)
PR 00 Detail not specified
PR 01 Order for wrong patient
PR 02 Order incorrectly entered online
+PR 03 Special needs not indicated on order
(e.g., CMV negative, auto)
PR 04 Order not done/incomplete/incorrect
PR 05 Inappropriate/incorrect test ordered
PR 06 Inappropriate/incorrect blood product
ordered
Sample Collection
SC 00 Detail not specified
+SC 01 Sample labeled with incorrect patient
name
+SC 02 Not labeled
+SC 03 Wrong patient collected
SC 04 Collected in wrong tube type
SC 05 Sample QNS
SC 06 Sample hemolyzed
+SC 07 Label incomplete/illegible/incorrect
(other than patient name)
SC 08 Sample collected in error
SC 09 Requisition arrived without samples
+SC 10 Wristband incorrect/not available
SC 11 Sample contaminated
Sample Handling
(Service Collecting Samples)
SH 00 Detail not specified
SH 01 Sample arrived without requisition
SH 02 Requisition and sample label don’t
match
+SH 03 Patient ID incorrect/illegible on
requisition
SH 05 No phlebotomist/witness identification
SH 06 Sample arrived with incorrect
requisition
SH 07 Patient information (other than ID)
missing/incorrect on requisition
SH 10 Sample transport issue
Sample Receipt
(Transfusion Service)
SR 00 Detail not specified
SR 01 Sample processed in error
SR 02 Historical review incorrect/not done
SR 03 Demographic review/data entry
incorrect/not done
SR 04 Sample incorrectly accessioned
(test/product)
SR 05 Duplicate sample sent
Sample Testing
(Transfusion Service)
ST 00 Detail not specified
ST 01 Data entry incorrect/not performed
ST 02 Appropriate sample checks not done
+ST 03 Computer warning overridden
ST 05 Sample tube w/incorrect accession label
+ST 07 Sample tubes mixed up
+ST 09 Test tubes mislabeled (wrong patient
name/number)
ST 10 Equipment problem
ST 12 Patient testing not performed
ST 13 Incorrect testing method chosen
ST 14 Testing performed incorrectly
ST 15 Test result misinterpreted
ST 16 Inappropriate/expired reagents used
ST 17 ABO/Rh error caught on final check
ST 18 Current and historical ABO/Rh don’t match
ST 19 Additional testing not performed
ST 20 Administrative check at time work performed
ST 22 Sample storage incorrect/inappropriate
Product Storage
(Transfusion Service)
US 00 Detail not specified
US 01 Incorrect storage of unit in transfusion service
US 02 Expired product in stock
US 03 Inappropriate monitoring of storage device
US 04 Unit stored on incorrect ABO shelf
Available for Issue
(Transfusion Service)
AV 00 Detail not specified
AV 01 Inventory audit
AV 02 Product status not/incorrectly updated in
computer
AV 03 Supplier recall
AV 04 Product ordered incorrectly/not submitted
Product Selection
(Transfusion Service)
SE 00 Detail not specified
SE 01 Incorrect product/component selected
SE 02 Data entry incomplete/incorrect
SE 03 Not/incorrect checking of product and/or patient
information
SE 05 Historical file misinterpreted/not checked
SE 07 Special processing needs not checked
SE 09 Special processing needs not understood or
misinterpreted
SE 11 Special processing not done
Product Manipulation
(Transfusion Service)
UM 00 Detail not specified
UM 01 Data entry incomplete/incorrect
UM 02 Record review incomplete/incorrect
UM 03 Wrong component selected
UM 04 Administrative check at time of manipulation
UM 05 Labeling incorrect
+UM 07 Special processing needs not checked
+UM 08 Special processing needs misunderstood or
misinterpreted
+UM 09 Special processing not/incorrectly done
Request for Pick-up
(Clinical Service)
RP 00 Detail not specified
RP 01 Request for pick-up on wrong
patient
RP 02 Incorrect product requested for
pick-up
RP 03 Product requested prior to obtaining
consent
RP 04 Product requested for pick-up
patient not available
RP 05 Product requested for pick-up IV
not ready
RP 06 Request for pick-up incomplete
RP 10 Product transport issue
Product Issue
(Transfusion Service)
UI 00 Detail not specified
UI 01 Data entry incomplete/incorrect
UI 02 Record review incomplete/incorrect
UI 03 Pick-up slip did not match patient
information
UI 04 Incorrect unit selected (wrong
person or right person, wrong order)
UI 05 Product issue delayed
+UI 06 LIS warning overridden
UI 07 Computer issue not completed
UI 09 Not/incorrect checking of unit and/or
patient information
UI 11 Unit delivered to incorrect location
UI 19 Wrong product issued
UI 20 Administrative review (self, 2nd 
check at issue)
UI 22 Issue approval not
obtained/documented
Product Administration
(Clinical Service)
UT 00 Detail not specified
+UT 01 Administered product to wrong
patient
+UT 02 Administered wrong product to
patient
UT 03 Product not administered
UT 04 Incorrect storage of product on floor
UT 05 Administrative review (unit/patient
at bedside)
UT 06 Administered product
w/incompatible IV fluid
UT 07 Administration delayed
UT 08 Wrong unit chosen from satellite
refrigerator
UT 10 Administered components in
inappropriate order
UT 11 Appropriate monitoring of patient
not done
UT 12 Floor/clinic did not check for
existing products in their area
UT 13 Labeling problem on unit
UT 19 Transfusion protocol not followed
Other
MS 99
+ Indicates high-priority incidents. Individual incident report must be completed for each.
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Appendix G. Incident Definitions
Incident Result
No Recovery, harm
Product was transfused and the patient experienced an adverse reaction.
No Recovery, no harm
Product was transfused, but the patient did not experience an adverse reaction.
Near miss, unplanned recovery
Product was not transfused. The incident was discovered ad hoc, by accident, a human lucky catch,
etc. It was not discovered through formalized facility standard operating procedures or other
previously instituted system of checks and balances to prevent such incidents.
Near miss, planned recovery.
Product was not transfused. The incident was discovered through standardized processes or barriers
built into the system to prevent errors.
Root Cause Analysis Result(s)
Technical:
•	 Technical failures beyond the control and responsibility of the facility.
•	 Failure due to poor design of equipment, software, labels or forms.
•	 Correct design but not constructed properly or set up in in-accessible areas
•	 Other material defects.
Organizational:
•	 Failure at an organizational level beyond the control and responsibility of the facility or
 
department where the incident occurred.
 
•	 Failure resulting from inadequate measures taken to ensure that situational or domain-specific
knowledge or information is transferred to all new or inexperienced staff.
•	 Failure relating to the quality and availability of the protocols/procedures within the department
(e.g., too complicated, inaccurate, unrealistic, absent or poorly presented).
•	 Internal management decisions when faced with conflicting demands or objectives. Failures
resulting from collective approach and its attendant modes of behavior to risks in the investigating
organization. These are organizational cultural attitudes and behaviors. For example, if the
organizational culture is one where compliance with safety related procedures is low or
procedures are not enforced.
Human:
•	 Human failures originating beyond the control and responsibility of the investigating organization.
This could include individuals in other departments.
•	 Inability of an individual to apply their existing knowledge to a novel situation. Example: a blood
bank technologist who is unable to solve a complex antibody identification problem.
•	 The incorrect fit between an individual’s training or education and a particular task. Example:
expecting a technician to solve the same type of difficult problem as a technologist.
•	 A lack of task coordination within a health care team. Example: an essential task not being
performed because everyone thought that someone else had completed the task.
•	 Incorrect or incomplete assessment of a situation including related conditions of the patient and
materials to be used before starting the transfusion. Example: failure to correctly identify the
patient by checking the wristband.
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•	 Faulty task planning and execution. Example: washing red blood cells using the same protocol as
that used for platelets.
•	 Failure in monitoring a process or patient status. Examples: a trained technologist operating an
automated instrument and not realizing that a pipette that dispenses a reagent is clogged. Failure
of the patient care staff to observe an allergic reaction in a patient after a transfusion is started.
•	 Failure in performance of highly developed skills. Example: a technologist adding drops of
reagents to a row of test tubes misses a tube or a computer entry error.
•	 Failure in whole body movements. “Slips, trips and falls.” Examples: a blood bag slipping out of
one’s hands and breaking; or a person tripping over a loose tile on the floor.
Patient-related:
•	 Failures related to patient characteristics or conditions which are beyond the control of staff and
influence treatment.
Other:
•	 Cannot be classified under any of the other categories.
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